1. Scrip
  2. >>Business
  3. >>Strategy

Genfit Assesses Optimal Elafibranor NASH Combo Therapy Opportunity

 
• By Joseph Haas

As it nears the Phase III data readout for elafibranor in NASH, Genfit plans combo therapy studies to determine if a GLP-1 analog or SGLT2 inhibitor would offer the best therapeutic synergy, market potential and partnership opportunity.

Old buildings on the Grand Place square at the evening, Lille, France - Image
Based in Lille, France, Genfit is one of five companies to reach Phase III in NASH

Genfit SA is ready to begin combination therapy studies of its Phase III non-alcoholic steatohepatitis (NASH) candidate elafibranor with two classes of already marketed diabetes drugs, but that does not mean it has found a partner for a potential combo regimen. The Lille, France-based company wants to get proof-of-concept data first so that it then can choose the partner associated with the greatest opportunity.

Genfit research and development head Dean Hum explained that moving into combination trials is part of the launch strategy for...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Strategy

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

More from Business

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 
• By Andrew McConaghie

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.